BIOMARKER:

KDM6A mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KDM6A mutation	Gastric Cancer	KDM6A mutation	Gastric Cancer	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B
KDM6A mutation	Acute Myelogenous Leukemia	KDM6A mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4
KDM6A mutation	Renal Cell Carcinoma	KDM6A mutation	Renal Cell Carcinoma	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D